Publications by authors named "Jane Meisel"

Claim this Profile
C
Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].
Isabelle Demeestere, Samuel M Niman, Ann H Partridge, Daniela S Diego, Roswitha Kammler, Jane Lowe Meisel

Breast· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani, Jane L Meisel

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of a Smart Label-Enabled Remote Therapeutic Monitoring Intervention to Support Cyclin-Dependent Kinase 4/6 Inhibitor Adherence in Breast Cancer Care.
Ilana Graetz, Sara Arshad, Clara Cai, Samuel Hernandez, Tamar Sapir, Jane Meisel

JCO Clin Cancer Inform· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD.
Gelareh Sadigh, Fenghai Duan, Ilana F Gareen, Judy Hancock, JoRean D Sicks, Jane L Meisel

Contemp Clin Trials· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.
Isabelle Demeestere, Samuel M Niman, Ann H Partridge, Daniela S Diego, Roswitha Kammler, Jane Lowe Meisel

Breast· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases.
Carey Anders, Edward Neuberger, Naomi R M Schwartz, Karen Bartley, Shu Wang, Jane Meisel

Int J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.
Erika P Hamilton, Manish R Patel, Virginia F Borges, Jane L Meisel, Meena Okera

Breast Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative 18F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.
Ismaheel O Lawal, Xiaoxian Li, Elizabeth A Sakach, Clara R Farley, Jane L Meisel

Clin Nucl Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.
Jane Lowe Meisel, Vyshak Alva Venur, Michael Gnant, Lisa Carey

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Shari B Goldfarb, Sarah L Sammons, Jane L Meisel, Timothy J Pluard, Simon N Jenkins

Clin Breast Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Jane Meisel

JCO Oncol Pract· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commission on Cancer Center Performance with the New Breast Cancer Quality Measures: A Review of Historical Data.
Marie L Fefferman, Danielle M Thompson, Lee G Wilke, Shelley Hwang, Richard Bleicher, Jane L Meisel

Ann Surg Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
Heather L McArthur, Sara M Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Jane Lowe Meisel

Ther Adv Med Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial.
Ilana Graetz, Samuel Hernandez, Sara Arshad, Kristina Byers, Jane Meisel

JCO Oncol Pract· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.
Veronica Jones, Hongwei Holly Yin, Yate-Ching Yuan, Yongzhe Wang, Sierra Min Li, Jane Meisel

Sci Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and transcriptomic landscape of HER2-low breast cancer.
Rani Bansal, Tolulope Adeyelu, Andrew Elliott, Phillip Walker, Matias A Bustos, Jane Meisel

Breast Cancer Res Treat· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
Rani Bansal, Tolulope Adeyelu, Andrew Elliott, Antoinette R Tan, Jennifer R Ribeiro, Jane Meisel

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
Aliza Mushtaq, Ismaheel O Lawal, Saima Muzahir, Sarah C Friend, Manali Bhave, Jane L Meisel

Eur J Nucl Med Mol Imaging· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial.
Ilana Graetz, Samuel Hernandez, Sara Arshad, Kristina Byers, Jane Meisel

JCO Oncol Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Jane Meisel

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
Sarah J Wood, Yuan Gao, Ji-Hoon Lee, Jessica Chen, Qun Wang, Jane L Meisel

Breast Cancer Res Treat· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer.
Xiaoxian Li, Ji-Hoon Lee, Yuan Gao, Jilun Zhang, Katherine M Bates, Jane Meisel

Mod Pathol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovsky-Strobl, Jane Lowe Meisel

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
Caitlin Taylor, Jane Meisel, Aimee J Foreman, Christy Russell, Dipankar Bandyopadhyay

Breast Cancer Res Treat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis